These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20018297)

  • 21. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunolocalization of liver receptor homologue-1 (LRH-1) in human breast carcinoma: possible regulator of insitu steroidogenesis.
    Miki Y; Clyne CD; Suzuki T; Moriya T; Shibuya R; Nakamura Y; Ishida T; Yabuki N; Kitada K; Hayashi S; Sasano H
    Cancer Lett; 2006 Nov; 244(1):24-33. PubMed ID: 16427184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
    Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
    Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of HER-2/neu expression in patients with ductal carcinoma in situ.
    Stackievicz R; Paran H; Bernheim J; Shapira M; Weisenberg N; Kaufman T; Klein E; Gutman M
    Isr Med Assoc J; 2010 May; 12(5):290-5. PubMed ID: 20929083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
    Nakamura Y; Yasuoka H; Tsujimoto M; Yang Q; Imabun S; Nakahara M; Nakao K; Nakamura M; Mori I; Kakudo K
    Clin Cancer Res; 2003 Nov; 9(14):5313-7. PubMed ID: 14614015
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence.
    Millar EK; Tran K; Marr P; Graham PH
    Pathol Int; 2007 Apr; 57(4):183-9. PubMed ID: 17316413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer.
    Serrano-Olvera A; Dueñas-González A; Gallardo-Rincón D; Candelaria M; De la Garza-Salazar J
    Cancer Treat Rev; 2006 May; 32(3):180-90. PubMed ID: 16483720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
    Niewiadomska H; Mirowski M; Stempień M; Błoński JZ; Czyz W; Switalska J; Matyga E; Hanausek M; Wierzbicki R
    Neoplasma; 2000; 47(1):8-14. PubMed ID: 10870681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
    Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
    Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclo-oxygenase type 2 is dysregulated in breast ductal carcinoma in situ and correlates with poor outcome.
    de la Torre J; Sabadell MD; Rojo F; Lirola JL; Salicru S; Reventos J; Ramón y Cajal S; Xercavins J
    Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):72-6. PubMed ID: 20227160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Study of HER2/neu status in Qatari women with breast carcinoma.
    Rasul KI; Mohammaed K; Abdalla AS; Chong-Lopez A; Ahmad MA; Al-Homsi MU; Al-Hassan AM; Al-Alosi AS; Bener A
    Saudi Med J; 2003 Aug; 24(8):832-6. PubMed ID: 12939666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen receptor alpha and beta, progesterone receptor, pS2 and HER-2/neu expression delineate different subgroups in ductal carcinoma in situ of the breast.
    Rody A; Diallo R; Poremba C; Speich R; Wuelfing P; Kissler S; Solbach C; Kiesel L; Jackisch C
    Oncol Rep; 2004 Oct; 12(4):695-9. PubMed ID: 15375487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
    Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
    Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability.
    Ballehaninna UK; Chamberlain RS
    J Clin Oncol; 2011 Feb; 29(4):e97-8; author reply e99. PubMed ID: 21172894
    [No Abstract]   [Full Text] [Related]  

  • 39. D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma.
    Rabban JT; Chen YY
    Hum Pathol; 2008 Feb; 39(2):175-83. PubMed ID: 18206495
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
    Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
    Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.